BACKGROUND: This study assesses the utility of a hybrid optical instrument for noninvasive transcranial monitoring in the neurointensive care unit. The instrument is based on diffuse correlation spectroscopy (DCS) for measurement of cerebral blood flow (CBF), and near-infrared spectroscopy (NIRS) for measurement of oxy- and deoxy-hemoglobin concentration. DCS/NIRS measurements of CBF and oxygenation from frontal lobes are compared with concurrent xenon-enhanced computed tomography (XeCT) in patients during induced blood pressure changes and carbon dioxide arterial partial pressure variation. METHODS: Seven neurocritical care patients were included in the study. Relative CBF measured by DCS (rCBF(DCS)), and changes in oxy-hemoglobin (DeltaHbO(2)), deoxy-hemoglobin (DeltaHb), and total hemoglobin concentration (DeltaTHC), measured by NIRS, were continuously monitored throughout XeCT during a baseline scan and a scan after intervention. CBF from XeCT regions-of-interest (ROIs) under the optical probes were used to calculate relative XeCT CBF (rCBF(XeCT)) and were then compared to rCBF(DCS). Spearman's rank coefficients were employed to test for associations between rCBF(DCS) and rCBF(XeCT), as well as between rCBF from both modalities and NIRS parameters. RESULTS: rCBF(DCS) and rCBF(XeCT) showed good correlation (r (s) = 0.73, P = 0.010) across the patient cohort. Moderate correlations between rCBF(DCS) and DeltaHbO(2)/DeltaTHC were also observed. Both NIRS and DCS distinguished the effects of xenon inhalation on CBF, which varied among the patients. CONCLUSIONS: DCS measurements of CBF and NIRS measurements of tissue blood oxygenation were successfully obtained in neurocritical care patients. The potential for DCS to provide continuous, noninvasive bedside monitoring for the purpose of CBF management and individualized care is demonstrated.
BACKGROUND: This study assesses the utility of a hybrid optical instrument for noninvasive transcranial monitoring in the neurointensive care unit. The instrument is based on diffuse correlation spectroscopy (DCS) for measurement of cerebral blood flow (CBF), and near-infrared spectroscopy (NIRS) for measurement of oxy- and deoxy-hemoglobin concentration. DCS/NIRS measurements of CBF and oxygenation from frontal lobes are compared with concurrent xenon-enhanced computed tomography (XeCT) in patients during induced blood pressure changes and carbon dioxide arterial partial pressure variation. METHODS: Seven neurocritical carepatients were included in the study. Relative CBF measured by DCS (rCBF(DCS)), and changes in oxy-hemoglobin (DeltaHbO(2)), deoxy-hemoglobin (DeltaHb), and total hemoglobin concentration (DeltaTHC), measured by NIRS, were continuously monitored throughout XeCT during a baseline scan and a scan after intervention. CBF from XeCT regions-of-interest (ROIs) under the optical probes were used to calculate relative XeCT CBF (rCBF(XeCT)) and were then compared to rCBF(DCS). Spearman's rank coefficients were employed to test for associations between rCBF(DCS) and rCBF(XeCT), as well as between rCBF from both modalities and NIRS parameters. RESULTS:rCBF(DCS) and rCBF(XeCT) showed good correlation (r (s) = 0.73, P = 0.010) across the patient cohort. Moderate correlations between rCBF(DCS) and DeltaHbO(2)/DeltaTHC were also observed. Both NIRS and DCS distinguished the effects of xenon inhalation on CBF, which varied among the patients. CONCLUSIONS:DCS measurements of CBF and NIRS measurements of tissue blood oxygenation were successfully obtained in neurocritical carepatients. The potential for DCS to provide continuous, noninvasive bedside monitoring for the purpose of CBF management and individualized care is demonstrated.
Authors: P Vajkoczy; H Roth; P Horn; T Lucke; C Thomé; U Hubner; G T Martin; C Zappletal; E Klar; L Schilling; P Schmiedek Journal: J Neurosurg Date: 2000-08 Impact factor: 5.115
Authors: Chao Zhou; Stephanie A Eucker; Turgut Durduran; Guoqiang Yu; Jill Ralston; Stuart H Friess; Rebecca N Ichord; Susan S Margulies; Arjun G Yodh Journal: J Biomed Opt Date: 2009 May-Jun Impact factor: 3.170
Authors: Anna Devor; Sava Sakadžić; Vivek J Srinivasan; Mohammad A Yaseen; Krystal Nizar; Payam A Saisan; Peifang Tian; Anders M Dale; Sergei A Vinogradov; Maria Angela Franceschini; David A Boas Journal: J Cereb Blood Flow Metab Date: 2012-01-18 Impact factor: 6.200
Authors: Erin M Buckley; Dalton Hance; Thomas Pawlowski; Jennifer Lynch; Felice B Wilson; Rickson C Mesquita; Turgut Durduran; Laura K Diaz; Mary E Putt; Daniel J Licht; Mark A Fogel; Arjun G Yodh Journal: J Biomed Opt Date: 2012-03 Impact factor: 3.170
Authors: Turgut Durduran; Chao Zhou; Erin M Buckley; Meeri N Kim; Guoqiang Yu; Regine Choe; J William Gaynor; Thomas L Spray; Suzanne M Durning; Stefanie E Mason; Lisa M Montenegro; Susan C Nicolson; Robert A Zimmerman; Mary E Putt; Jiongjiong Wang; Joel H Greenberg; John A Detre; Arjun G Yodh; Daniel J Licht Journal: J Biomed Opt Date: 2010 May-Jun Impact factor: 3.170
Authors: David R Busch; Ramani Balu; Wesley B Baker; Wensheng Guo; Lian He; Mamadou Diop; Daniel Milej; Venkaiah Kavuri; Olivia Amendolia; Keith St Lawrence; Arjun G Yodh; W Andrew Kofke Journal: Neurocrit Care Date: 2019-02 Impact factor: 3.210
Authors: Karthik Vishwanath; Rajan Gurjar; David Wolf; Suzannah Riccardi; Michael Duggan; David King Journal: Biomed Opt Express Date: 2018-01-11 Impact factor: 3.732
Authors: David R Busch; Regine Choe; Turgut Durduran; Daniel H Friedman; Wesley B Baker; Andrew D Maidment; Mark A Rosen; Mitchell D Schnall; Arjun G Yodh Journal: Acad Radiol Date: 2014-02 Impact factor: 3.173
Authors: Songfeng Han; Ashley R Proctor; Joseph B Vella; Danielle S W Benoit; Regine Choe Journal: Biomed Opt Express Date: 2016-08-09 Impact factor: 3.732